vs
Side-by-side financial comparison of Fatpipe Inc (FATN) and Taysha Gene Therapies, Inc. (TSHA). Click either name above to swap in a different company.
Taysha Gene Therapies, Inc. is the larger business by last-quarter revenue ($5.5M vs $4.1M, roughly 1.3× Fatpipe Inc). Fatpipe Inc runs the higher net margin — 7.6% vs -507.8%, a 515.4% gap on every dollar of revenue. On growth, Taysha Gene Therapies, Inc. posted the faster year-over-year revenue change (171.3% vs 3.2%).
Taysha Gene Therapies, Inc. is a clinical-stage biotechnology company specializing in developing adeno-associated virus (AAV)-based gene therapies for rare monogenic central nervous system disorders with high unmet medical needs. Its core pipeline targets serious life-threatening neurological conditions, with primary operations and market focus across North America and European regions.
FATN vs TSHA — Head-to-Head
Income Statement — Q3 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $4.1M | $5.5M |
| Net Profit | $310.7K | $-27.9M |
| Gross Margin | 87.7% | — |
| Operating Margin | 9.8% | -516.0% |
| Net Margin | 7.6% | -507.8% |
| Revenue YoY | 3.2% | 171.3% |
| Net Profit YoY | 816.0% | -48.3% |
| EPS (diluted) | $0.02 | $-0.08 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $4.1M | $5.5M | ||
| Q3 25 | $4.0M | $0 | ||
| Q2 25 | $3.9M | $2.0M | ||
| Q1 25 | — | $2.3M | ||
| Q4 24 | — | $2.0M | ||
| Q3 24 | — | $1.8M | ||
| Q2 24 | — | $1.1M | ||
| Q1 24 | — | $3.4M |
| Q4 25 | $310.7K | $-27.9M | ||
| Q3 25 | $-43.4K | $-32.7M | ||
| Q2 25 | $741.2K | $-26.9M | ||
| Q1 25 | — | $-21.5M | ||
| Q4 24 | — | $-18.8M | ||
| Q3 24 | — | $-25.5M | ||
| Q2 24 | — | $-20.9M | ||
| Q1 24 | — | $-24.1M |
| Q4 25 | 87.7% | — | ||
| Q3 25 | 92.1% | — | ||
| Q2 25 | 94.2% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | 9.8% | -516.0% | ||
| Q3 25 | -0.0% | — | ||
| Q2 25 | 25.5% | -1347.1% | ||
| Q1 25 | — | -930.5% | ||
| Q4 24 | — | -985.8% | ||
| Q3 24 | — | -1448.4% | ||
| Q2 24 | — | -1915.4% | ||
| Q1 24 | — | -713.3% |
| Q4 25 | 7.6% | -507.8% | ||
| Q3 25 | -1.1% | — | ||
| Q2 25 | 18.8% | -1353.6% | ||
| Q1 25 | — | -935.2% | ||
| Q4 24 | — | -929.0% | ||
| Q3 24 | — | -1427.5% | ||
| Q2 24 | — | -1882.0% | ||
| Q1 24 | — | -705.4% |
| Q4 25 | $0.02 | $-0.08 | ||
| Q3 25 | $0.00 | $-0.09 | ||
| Q2 25 | $0.05 | $-0.09 | ||
| Q1 25 | — | $-0.08 | ||
| Q4 24 | — | $-0.07 | ||
| Q3 24 | — | $-0.10 | ||
| Q2 24 | — | $-0.09 | ||
| Q1 24 | — | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $319.8M |
| Total DebtLower is stronger | $4.6M | — |
| Stockholders' EquityBook value | $21.2M | $246.9M |
| Total Assets | $32.4M | $343.3M |
| Debt / EquityLower = less leverage | 0.22× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $319.8M | ||
| Q3 25 | — | $297.3M | ||
| Q2 25 | — | $312.8M | ||
| Q1 25 | — | $116.6M | ||
| Q4 24 | — | $139.0M | ||
| Q3 24 | — | $157.7M | ||
| Q2 24 | — | $172.7M | ||
| Q1 24 | — | $124.0M |
| Q4 25 | $4.6M | — | ||
| Q3 25 | $4.8M | — | ||
| Q2 25 | $4.9M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $21.2M | $246.9M | ||
| Q3 25 | $21.0M | $219.0M | ||
| Q2 25 | $20.4M | $248.7M | ||
| Q1 25 | — | $55.1M | ||
| Q4 24 | — | $71.5M | ||
| Q3 24 | — | $88.8M | ||
| Q2 24 | — | $108.9M | ||
| Q1 24 | — | $53.8M |
| Q4 25 | $32.4M | $343.3M | ||
| Q3 25 | $32.2M | $316.6M | ||
| Q2 25 | $32.0M | $333.3M | ||
| Q1 25 | — | $138.4M | ||
| Q4 24 | — | $160.4M | ||
| Q3 24 | — | $180.2M | ||
| Q2 24 | — | $200.4M | ||
| Q1 24 | — | $153.0M |
| Q4 25 | 0.22× | — | ||
| Q3 25 | 0.23× | — | ||
| Q2 25 | 0.24× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $240.9K | $-26.7M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | 0.78× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $240.9K | $-26.7M | ||
| Q3 25 | $399.8K | $-24.2M | ||
| Q2 25 | $-508.6K | $-20.2M | ||
| Q1 25 | — | $-22.0M | ||
| Q4 24 | — | $-18.3M | ||
| Q3 24 | — | $-21.6M | ||
| Q2 24 | — | $-21.5M | ||
| Q1 24 | — | $-19.8M |
| Q4 25 | — | — | ||
| Q3 25 | — | $-24.3M | ||
| Q2 25 | $-551.1K | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $-18.3M | ||
| Q3 24 | — | $-21.6M | ||
| Q2 24 | — | $-21.7M | ||
| Q1 24 | — | $-19.9M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -14.0% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -905.5% | ||
| Q3 24 | — | -1210.9% | ||
| Q2 24 | — | -1951.9% | ||
| Q1 24 | — | -584.5% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 1.1% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.1% | ||
| Q3 24 | — | 2.0% | ||
| Q2 24 | — | 18.1% | ||
| Q1 24 | — | 4.1% |
| Q4 25 | 0.78× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -0.69× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FATN
| Products | $2.6M | 63% |
| Other | $1.5M | 37% |
TSHA
Segment breakdown not available.
